YBX1 and breast cancer: When YBX1 was overexpressed in breast cancer cells with stable CD2BP2‐DT knockdown, the proliferation inhibition caused by CD2BP2‐DT knockdown was partially reversed (Figure 3O,P; Figure S3H,I, Supporting Information).